TACI-immunoglobulin fusion proteins
US7501497B2 · kind B2 · utility
20Cited by
8References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2005 |
| Grant date | Mar 10, 2009 |
| Priority date | — |
| Expiry date | Oct 19, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.